11/15
08:48 am
mirm
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results [Yahoo! Finance]
Medium
Report
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results [Yahoo! Finance]
11/14
08:22 am
mirm
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting [Yahoo! Finance]
11/14
08:00 am
mirm
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
Low
Report
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
11/14
05:54 am
mirm
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/13
02:43 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.
11/13
12:53 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $65.00 to $68.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $65.00 to $68.00. They now have a "buy" rating on the stock.
11/13
08:05 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Robert W. Baird from $44.00 to $50.00. They now have an "outperform" rating on the stock.
Medium
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Robert W. Baird from $44.00 to $50.00. They now have an "outperform" rating on the stock.
11/13
02:26 am
mirm
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... [Yahoo! Finance]
11/12
01:53 pm
mirm
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/12
01:04 pm
mirm
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised [Yahoo! Finance]
Medium
Report
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised [Yahoo! Finance]
11/12
11:02 am
mirm
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
08:00 am
mirm
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/8
06:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/7
04:30 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
11/4
04:45 pm
mirm
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 [Yahoo! Finance]
11/4
04:30 pm
mirm
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Low
Report
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
10/31
08:30 am
mirm
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
Low
Report
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
10/17
11:36 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Leerink Partners from $47.00 to $49.00. They now have an "outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Leerink Partners from $47.00 to $49.00. They now have an "outperform" rating on the stock.
10/11
08:41 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.
Medium
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.
10/10
07:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10
08:30 am
mirm
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
Low
Report
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
9/10
08:45 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/28
04:01 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Medium
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences